Turing Pharmaceuticals CEO Martin Shkreli announced Tuesday night that the company will roll back the price of the drug Daraprim, but did not commit to a specific price.
The company had faced intense criticism in recent days from patient advocacy groups, doctors, politicians -- as well as from within its own industry -- after it raised the price of the 62-year-old drug from $18 to $750 or more than 4,000 percent after it purchased rights to the drug last month. The medication is a critical treatment for a parasitic infection that can be fatal to those with compromised immune systems due to conditions like AIDS/HIV and cancer.
